FRANCISCO DE PAULA
TELLEZ PEREZ
Profesor asociado de Ciencias de la Salud
Hospital Regional Universitario de Málaga
Málaga, EspañaPublications en collaboration avec des chercheurs de Hospital Regional Universitario de Málaga (20)
2021
-
Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy
Journal of Hepatology, Vol. 74, Núm. 4, pp. 801-810
-
Progression to hepatitis C virus micro-elimination in people living with HIV in Spain
Clinical Microbiology and Infection
2020
-
Impact of HIV on the survival of hepatocellular carcinoma in hepatitis C virus-infected patients
AIDS (London, England), Vol. 34, Núm. 10, pp. 1497-1507
-
What is needed to achieve HCV microelimination among HIV-infected populations in Andalusia, Spain: A modeling analysis
BMC Infectious Diseases, Vol. 20, Núm. 1
2019
-
Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes
Journal of Hepatology
-
DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients
Medicine (United States), Vol. 98, Núm. 32
-
Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients
AIDS, Vol. 33, Núm. 2, pp. 269-278
-
Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients
HIV Medicine, Vol. 20, Núm. 6, pp. 359-367
2018
-
Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients
AIDS, Vol. 32, Núm. 11, pp. 1423-1430
2017
-
Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 3, pp. 487-494
-
Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients
AIDS, Vol. 31, Núm. 1, pp. 89-95
-
Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection
Clinical Microbiology and Infection, Vol. 23, Núm. 6, pp. 409.e5-409.e8
2016
-
Clinical, virological and phylogenetic characterization of a multiresistant HIV-1 strain outbreak in naive patients in southern Spain
Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 2, pp. 357-361
-
Effectiveness of ritonavir-boosted protease inhibitor monotherapy in clinical practice even with previous virological failures to protease inhibitor-based regimens
PLoS ONE, Vol. 11, Núm. 2
-
Hepatic safety of rilpivirine/emtricitabine/tenofovir disoproxil fumarate fixed-dose single-tablet regimen in HIV-infected patients with active hepatitis C virus infection: The hepatic study
PLoS ONE, Vol. 11, Núm. 5
-
No evidence of firstly acquired acute hepatitis C virus infection outbreak among HIV-infected patients from Southern Spain: A multicentric retrospective study from 2000-2014
BMC Infectious Diseases, Vol. 16, Núm. 1
2015
-
Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 11, pp. 2247-2255
-
Low efficacy of pegylated interferon plus ribavirin plus nitazoxanide for HCV genotype 4 and HIV coinfection
PLoS ONE, Vol. 10, Núm. 12
2014
2011
-
Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C
Journal of Antimicrobial Chemotherapy, Vol. 66, Núm. 6, pp. 1346-1350